OUR NEW PROFILE IS: (NASDAQ: ATNM)
Can a Flagship Phase III Trial and Cutting-Edge Phase 1 Trial Help This Innovator Cure Active, Relapsed, or Refractory Acute Myeloid Leukemia?
*****BREAKING NEWS RELEASED THIS MORNING*****
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
Read the INVESTOR PRESENTATION HERE
________________________________
Hello Everyone,
I hope that you have been following our profiles. They have been on fire the past few months. All of our recent alerts have gone on to make double digit moves in the days/weeks after we have released them.
This next one is a potentially explosive Biotech that has been trading fairly sideways in 2022. It is our hope that ATNM can bust out of its channel and climb the ladder back to 2021 prices.
It is no secret that biotechs can start as little known afterthoughts and turn into explosive disruptors on the cusp of revolutionizing medicine in months, weeks, or even days.
For example, did you even know who Moderna was 2 years ago?
On March 20, 2020, Moderna was nothing but a little-known biotech innovator developing an experimental vaccine trading at $30.05. Within the last 52-week period (as of 4/7/22)? It hit a high of $497.59 for a move of over 1,500%! (Source 2)
Amidst the continued carnage of the worldwide health situation, many biotech stockshave seen their shares skyrocket to incredible highs in 2022 year-to-date (as of 4/7/22): (Source 3)
- Pulmatrix, Inc. 1,530.06%
- Celsion Corporation 863.16%
- Baudax Bio, Inc. 723.27%
- Voyager Therapeutics, Inc. 230.07%
- CTI BioPharma Corp. 110.89%
Get this, though.
How many well-respected analysts gave them a price target showing significant upside potential? (Source 4)
Are any of those stocks in the midst of a Phase 3 trial that could potentially cure one of the most debilitating forms of cancer we know- relapsed or recurrent, acute myelogenous leukemia (AML)?
Meet Actinium Pharmaceuticals (NYSE: ATNM). This clinical-stage biopharmaceutical company could completely revolutionize medicine. All by developing targeted radiotherapies that deliver cancer-killing radiation with cellular-level precision.
Based on recent history, when biotech companies find a solution, the results can be life-changing. Keep a very close eye on this company as its Iomab-B treatment progresses through Phase III SIERRA trials.
Actinium Pharmaceuticals (NYSE: ATNM) could be next!
*****NEWS RELEASED THIS MORNING*****
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
– Data show enhanced antitumor effects and improved survival were observed in a preclinical NSCLC model compared to a naked HER3 antibody
– HER3 targeted radiotherapy represents a novel therapeutic strategy for tumors expressing HER3 and tumors with acquired resistance to HER1/2 therapies.
– Data Supports Actinium Pharmaceutical’s research collaboration with AVEO Oncology to develop and advance a HER3 targeted radiotherapy to clinical studies
NEW YORK, April 11, 2022 /PRNewswire/ — Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells. These data were presented at the American Association of Cancer Research (AACR 2022) annual meeting, which is being held April 8th – 13th at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
- Ac-225-HER3 antibody radio conjugate (ARC) eliminated HER3-postive tumors in an in vivo animal model of human non-small cell lung cancer (NSCLC) at multiple dose levels with increased survival
- A dose-dependent cytotoxic effect against HER3 expressing cells was observed in vitro with the Ac-225-HER3-ARC
- Biodistribution data demonstrates accumulation of the Ac-225-HER3-ARC in HER3 expressing tumors in the in vivo model of NSCLC
- Conjugation of Ac-225 to the HER3 antibody did not affect the antibody’s targeting properties as determined by binding to HER3 expressing cells
Dr. Helen Kotanides, Vice President, Translational Research and Preclinical Development, stated, “HER3 is a well-validated target that is overexpressed in a number of cancers and associated with poor survival in breast, ovarian, lung, gastric and prostate cancer. It is also upregulated in response to HER1 and HER2 targeted therapies as part of acquired resistance against these EGFR therapies. These data show that arming a HER3-targeting agent with Actinium-225 results in potent anti-tumor agent, which improved survival in our NSCLC models. These data support our goal of developing a HER3 targeted radiotherapy for use in a patient population in need of new treatments and give us great excitement for our ongoing collaboration with AVEO centered around HER3.”
Sandesh Seth, Chairman and CEO of Actinium, stated, “We are excited to continue to demonstrate Actinium’s enhanced R&D capabilities and commitment to developing potent radiotherapies targeting solid tumors. We look forward to sharing these data, which show the efficacy for our novel approach of conjugating Actinium-225 to a HER3 antibody at AACR 2022. The development of Ac-225-HER3-ARC, a product of our validated Antibody Warhead Enabling (AWE) technology platform, represents a departure from conventional HER3-targeting approaches, such as naked antibodies and antibody drug conjugates, that are currently being explored for this tumor antigen. These exciting data highlight Actinium’s leadership in developing novel targeted radiotherapy approaches for treating cancers having high unmet needs.”
__________________________________
There is Demand For a Leukemia Cure…and the Market Looks Lucrative
Do you know what’s driving this market? A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The increasing number of approvals of novel & innovative dr-ugs and immunotherapies is evidence of an increasing need for leukemia therapies. (Source 5)
Say hello to a wide-open opportunity for Actinium Pharmaceuticals (NYSE: ATNM).
Treatment options for AML, or acute myeloid leukemia, is precisely an unmet need- especially for those under 45. According to Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, as quoted by Check Rare, (Source 6) it is rarely diagnosed in patients under the age of 45.
At the moment, the five-year survival rate for those 20 and older is also putrid 26%. (Source 7)
Some must also contend with relapsed, or recurrent, acute myelogenous leukemia(AML), which means leukemia came back after treatment and after reaching remission. Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells. (Source 8)
Actinium’s Iomab-B Could Be Nearing a Treatment With SIERRA trials
When you want to find a biotech play, you have to think this way- “don’t talk about it, be about it.”
Well, Actinium isn’t just talking the talk, they’re walking the walk.
On September 15, Actinium announced enrollment for its pivotal Phase III SIERRA trial of Iomab-B was complete. (Source 1)
SIERRA is a 150-patient, multicenter, randomized trial studying Iomab-B, an antibody-radiation conjugate comprising an anti-CD45 antibody and radioactive iodine-131 (I-131), compared with salvage chemotherapy inactive, relapsed, or refractory acute myeloid leukemia (AML).
“Iomab-B was developed to address the significant unmet need of patients who could benefit and possibly be cured of their blood cancer with a bone marrow transplant but could not receive a transplant because non-targeted conditioning regimens could not produce a remission or are too toxic in this patient population. We are confident that Iomab-B will squarely address this unmet need given its targeted nature and ability to deliver high amounts of radiation directly to the bone marrow resulting in myeloablation while sparing healthy organs,” said Dr. Avinash Desai, Actinium Pharmaceuticals’ Executive VP, Clinical Development. (Source 9)
The company’s Chief Medical Officer, Avinash Desai said: (Source 17)
“The remarkably consistent and high rates of BMT engraftment together with the low rates of non-relapse transplant-related mortality at day 100 with Iomab-B through 100% enrollment give us great confidence in SIERRA.”
And the company’s press release added more:
– Consistent 5-times greater difference between Iomab-B vs Control arm at each 100-day NR-TRM (non-relapse transplant-related mortality) interim analysis of the SIERRA trial
– Control arm therapies failed to achieve remission in 83% of patients with just 14% of patients being potentially evaluable at 100-day NR-TRM for the primary endpoint compared to 100% BMT engraftment with Iomab-B and 70% of patients potentially evaluable for the primary endpoint
– Unmet need in relapsed and refractory AML demonstrated by 66% of patients enrolled in SIERRA having received and failed targeted therapies prior to enrollment
– Significantly lower rate of sepsis (p=0.002) and lower rates of febrile neutropenia in patients receiving Iomab-B compared to salvage therapy in the control arm
With this info coming out at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH), could it help spark additional interest in Actinium?
In short, if things continue progressing the way they are, Actinium Pharmaceuticals (NYSE:ATNM) could be a game-changer.
The SIERRA Trial is the ONLY Randomized Phase 3 Trial to Offer Bone Marrow Transplants (BMT) (Source 9)
The company’s SIERRA trial for Iomab-B is a 150-patient, randomized 1:1 pivotal Phase 3 trial studying Iomab-B compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed, or refractory AML or acute myeloid leukemia. (Source 9)
Cool right?
Here’s the kicker, though. This trial is believed to be the ONLY randomized Phase 3 trial to offer BMT, the only potentially curative treatment option, to this patient population. (Source 9)
Plus, Iomab-B is a radiotherapy that targets cells expressing CD45. This protein is found only on blood cancer cells and immune cells, including bone marrow stem cells, with the radioisotope iodine-131. It is intended to be a targeted conditioning agent to enable potentially curative BMTs. (Source 9)
This could completely revolutionize the medical community…especially when you consider how impressive trial data already looks: (Source 12)
- 100% engraftment consistent throughout interim analyses at 25%, 50%, and 75% of patient enrollment despite heavy leukemia burden before Iomab-B treatment.
- Personalized Iomab-B therapy enables targeted delivery of radiation to the bone marrow enabling myeloablation in a well-tolerated manner.
- Iomab-B delivers high amounts of targeted radiation to the bone marrow with minimal impact on other organs resulting in lower rates and severity of adverse events.
The Strengthening Its Patent Portfolio with International IP
Why limit yourself to one domestic market if you have such a potentially strong treatment candidate that could change the entire world?
Actinium recently announced that its intellectual property portfolio around Iomab-B has been further strengthened internationally. (Source 13)
- In the EU, Actinium has been issued a patent covering the composition and methods of administration of Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131. The issued patent in the EU is expected to have a useful life through 2036.
- In addition, Actinium has been granted a patent covering the same composition and methods of administration claims in Japan.
- According to Dr. Dale Ludwig, Actinium’s Chief Scientific Officer:
“We are excited to expand our already robust patent portfolio with these key patents in the EU and Japan. As the only CD45 ARC for targeting conditioning in clinical development, these international patents, together with our U.S. patents lay the foundation for aggressive development of Iomab-B for BMT conditioning and Iomab-ACT for conditioning prior to cell and gene therapies. Iomab-B is well characterized and supported by extensive clinical data across multiple clinical trials and indications.”
“Our ARC approach has significant advantages over other approaches such as monoclonal antibodies or antibody-drug conjugates that require payload internalization, making them impractical for targeting CD45. We look forward to continuing to build our leadership position in targeted conditioning led by Iomab-B and remaining at the forefront of innovation in targeted radiotherapy.”
Analysts Are Going Crazy Over ATNM’s Potential Upside
While the ATNM stock did pull back in recent months, it may have caught strong double bottom support around $4.41.
Many analysts are also not just going long on this stock. They’re going all in.
William Blair, for one, gives the stock an “Outperform” rating with a risk-adjusted fair value of $11.12 per share value. (Source 10)
Blair also stated that the “company finished the second quarter with a cash level of $81.9 million, which according to our estimates will likely sustain company operations into the first half of 2023, potentially beyond the Phase III SIERRA trial top-line readout.” (Source 10)
Most importantly, “Pending positive results from the Phase III SIERRA study and successful regulatory interactions with the FDA, [Iomab-B] is poised to disrupt the $600 million preconditioning market in the United States and Europe.” (Source 10)
Other analysts are even more bullish on the stock.
After ATNM announced full enrollment for its Phase III SIERRA Trial, Jones Trading immediately gave the company a $40 price target. (Source 16) Moreover, Jones Trading forecasted Actinium to see approximately $500 million in peak sales by 2032. (Source 16)
But what if I told you that this isn’t even the most bullish analyst call?! H.C. Wainwright gave the stock a $45 price target! (Source 4) That would give it potentially 773% upside (from close 4/7/22) of room to run!
773%!
Based on this rating, H.C. Wainwright says that “the common stock of the company is expected to outperform a passive index composed of all the common stock of companies within the same sector.” (Source 4)
But wait, there’s more…
Along with AVEO Technology, ATNM just entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3, which is overexpressed in several solid tumor indications with high unmet needs, including colorectal, gastric, head and neck, breast, ovarian, melanoma, prostate and bladder cancers. (Source 25)
That could be substantial.
Even more impressive, Actinium just announced it entered into a research collaboration to study Actinium’s Actimab-A targeted radiotherapy in combination with RR-001, EpicentRx’s novel small molecule immunotherapy targeting AML. (Source 26)
It is no secret that biotech stocks are either hit or miss. But when they hit, the potential upside can be massive. Actinium Pharmaceuticals (NYSE: ATNM) could be our latest and most significant find in the biotech sector. It has a potentially revolutionary treatment rapidly progressing and the possibility to change the face of medicine as we know it.
And analysts see it.
If you don’t watch this one closely, you may regret it.
Management Team
Sandesh Seth
Chief Executive Officer and Chairman of the Board
Mr. Seth has 25+ years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Mr. Seth was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Mr. Seth has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.
Avinash Desai, MD
Chief Medical Officer
Dr. Desai is an industry veteran in the hematology and oncology field, most recently serving as Vice President, Head of U.S. Medical Affairs – Oncology at Glaxo Smith Kline (GSK). Over the course of his twenty-five-year career, Dr. Desai has successfully designed and implemented clinical development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data and Safety Monitoring Boards (DSMB) for hematology, oncology and therapeutic candidates. At GSK, he established the U.S. medical affairs oncology team that oversaw the launch readiness plans for three novel oncology products—Blenrep® in multiple myeloma, Zejula® in ovarian cancer, and dostarlimab in endometrial cancer. In addition to GSK, Dr. Desai has overseen the clinical development, implementation and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies, including Eli Lilly & Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc. Prior to GSK, he was the VP of Global Medical Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly’s GI Oncology portfolio. Earlier in his career, Dr. Desai contributed to the approval of Janssen’s myeloma drug Darzalex® (daratumumab) and leading and strategically executing medical affairs activities globally for Velcade® (bortezomib). Prior to Janssen, Dr. Desai was responsible for the international development of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed pivotal trials that led to NDA submission for Jevtana® (cabazitaxel).
Arun Swaminathan, Ph.D.
Chief Business and Commercial Officer
Dr. Swaminathan is a highly accomplished executive with over 20 years of experience in the global biopharmaceutical industry, which has included increasing positions of responsibility across commercial, business development, and clinical roles. He has a proven track record of converting great science into successful business opportunities. Prior to joining Actinium, Dr. Swaminathan was the Chief Business Officer and Senior Vice President at Alteogen Inc. a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics. In this role, his negotiations with partners led to deals totaling over $6 billion in potential value, including agreements with two of the top ten global pharmaceutical companies. During his tenure at Alteogen, the Company’s market value increased from approximately $400 million to over $4 billion. Dr. Swaminathan joined Alteogen after they entered into an agreement with Lynkogen Inc. and gained full rights to develop the assets. As CEO and co-founder of Lynkogen, he raised capital, in-licensed potentially transformative drug candidates to address complex metabolic diseases and advanced Lynkogen from concept to a pre-clinical stage company with a lead drug candidate ready for IND enabling studies that he successfully negotiated for out-licensing. Previously, Dr. Swaminathan held commercial and business development roles at Bristol Myers Squibb over 12 years during two tenures, most recently as Worldwide Brand Director, where he managed products with over $2 billion in annual sales across the top 10 global markets. Earlier at BMS, Dr. Swaminathan advanced from principal scientist to associate director, working on approved products including Nulojix®, Orencia® and Eliquis®. Between his tenures at BMS, he spent nearly four years at Covance (now Labcorp Drug Development), where he rose to Marketing Head, in charge of a $1 billion clinical business. Dr. Swaminathan received his Ph.D., Pharmaceutical Sciences at the University of Pittsburgh, and is a graduate of the Marketing Management Program at Wharton, University of Pennsylvania.
Steve O’Loughlin
Chief Financial Officer
Mr. O’Loughlin joined Actinium in October 2015 as Vice President, Finance and Corporate Development and was named Principal Financial Officer in May 2017 and Chief Financial Officer in July 2020. Steve possesses nearly fifteen years of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to October 2015, Mr. O’Loughlin worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Mr. O’Loughlin held the position of Vice President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences company developing and commercializing mass spectrometry imaging and bioanalytic technologies and services. Previously, From June 2010 to June 2012, Mr. O’Loughlin held corporate development positions with Caliber I.D., (formerly Lucid, Inc.) a publicly traded company developing and commercializing VivaScope ®, an FDA cleared diagnostic device for the non-invasive assessment of the skin for skin cancer and other dermatologic conditions. Mr. O’Loughlin previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Mr. O’Loughlin has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey.
Helen Kotanides, Ph.D.
Vice President, Translational Research and Preclinical Development
Dr. Kotanides joins Actinium from Eli Lilly after a distinguished career with continued succession through multiple positions culminating as Senior Research Advisor, Cancer Immunobiology. Dr. Kotanides brings nearly 25 years of R&D experience from ImClone Systems and then Eli Lilly with a focus on the preclinical discovery and development of oncology biologic drugs. She has extensive first-hand knowledge and experience in cancer biology and immunotherapy, including target discovery and the testing, development, and advancement of biologics, immune checkpoint therapies, and targeted therapies. As a result, Dr. Kotanides has led several preclinical programs to successful IND filings. Dr. Kotanides received her Ph.D. in Molecular Biology and Biochemistry from the State University of New York at Stony Brook, her master’s degree in Biology from New York University and her bachelor’s degree in Biology from Clark University.
Monideepa Roy, Ph.D.
Vice President, Corporate Development – R&D
Dr. Roy is a scientist-entrepreneur whose experience includes tenure as CEO of an early-stage oncology drug development company and nearly a decade in academic experience that includes training and work experience at Harvard Medical School/Brigham and Women’s Hospital. Dr. Roy joins Actinium from Akamara Therapeutics, where she most recently served as Vice President, Corporate Development and Operations. As a founding member and interim CEO at Akamara, she played a critical role in recruiting an executive team, establishing the Company’s corporate and R&D strategy, operational execution and growing the global team from 4 to 40. During her tenure at Akamara, she contributed to partnership/collaboration efforts, developed portfolio strategies, evaluated technology platforms, oversaw research activities to support IND filings, led regulatory preparation and submissions, and worked to generate and secure intellectual property. Prior to Akamara, she was Director, Research and Development at Invictus Oncology Pvt. Ltd., a drug discovery company developing novel I/O and conjugated antibody therapies. Here she co-led the licensing of technology from Brigham and Women’s Hospital, raised Series A financing, established the Company’s strategy around a B-cell immunotherapy platform and established an international research capability to advance the Company’s technologies. Additionally, she established a network of KOLs and identified and evaluated supramolecular platform technologies. Prior to industry, Dr. Roy was a Lecturer at Harvard University, was a Leukemia and Lymphoma Society Special Fellow and Research Fellow, Dept. Of Pathology at Brigham and Women’s Hospital/Harvard Medical School. Dr. Roy received her Ph.D. in Molecular Biology from Jawaharlal Nehru University, her master’s degree in Biophysics and Molecular Biology from the University College of Science, Calcutta and her bachelor’s degree in Human Physiology from Presidency College, Calcutta.
Dr. Mary Mei Chen, M.D., Ph.D.
Vice President, Clinical Development
Dr. Chen received training in both hematology (M.D.) and immunology (Ph.D.) followed by over twenty years of clinical research and development experience, including over ten years of biopharmaceutical industry experience and five years as a practicing hematologist. During her time in industry, she has led global, cross-functional teams in the design and execution of first-in-human clinical trials as well as trials in Phase 1 through Phase 3 in patients with AML, multiple myeloma, and breast cancer. She has contributed to the preparation and submission of regulatory documents and attended regulatory meetings to support Investigational New Drug (IND) and NDA applications in the US, EU, and other regions. Over the course of her career, she has authored over 50 peer reviewed publications in high impact journals. Dr. Chen joins Actinium from GlycoMimetics, Inc., where she led multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301), which is enrolling 380 patients with R/R AML at approximately 50 centers across nine countries. In this effort, Dr. Chen managed relationships with study investigators, created necessary protocols, Investigational Brochures, and target product profiles. Previously, Dr. Chen held the position of Medical Director, Global Clinical Lead–Clinical Science at Takeda Pharmaceuticals International where she developed clinical trials and protocols for T-cell and B-cell targeting therapies for oncology and inflammatory diseases. In this role, she successfully led multidisciplinary teams in the submission of an IND and Clinical Trial Application. Prior to Takeda, Dr. Chen worked at Pfizer (Wyeth), as Translational Medicine Team Lead-Translational Immunology. In this role, Dr. Chen supported biomarker development to support clinical development in hematology, oncology and inflammatory diseases for biologic and small molecules. At Pfizer, she contributed to the scientific, clinical and commercial development of the R&D pipeline and coordinated clinical development plans and protocols.
Prior to the biopharmaceutical industry, Dr. Chen was a researcher at the Harvard Medical School, Brigham and Women’s Hospital in the Department of Immunology, Rheumatology and Allergy, initially as a Postdoctoral Fellow before becoming Faculty Member, Instructor in Medicine. Mary received her Ph.D. in Immunology from Chiba University, Graduate School of Medicine in Tokyo, Japan. She completed her postdoctoral fellowship in the department of infection and host disease at Chiba University. Dr. Chen received her Doctor of Medicine degree from Shanghai Jiao Tong University, School of Medicine.
Paul Diamond, Ph.D., J.D.
Vice President, Patent and Legal Counsel
Dr. Diamond joins Actinium with over 20 years of experience in patent law, developing and executing IP strategy within the biotechnology industry. He joins Actinium from Enzo Biochem, Inc., where he was Senior Counsel, Patents and Business Development. As Enzo’s sole patent attorney and senior-most counsel, he reported to the CEO and led all IP related and essential in-house legal functions. During his time at Enzo, Dr. Diamond obtained critical, high-value patent coverage for key products and technologies and managed high-profile litigations and settlement negotiations that resulted in a number of sizeable settlements. Prior to Enzo, Dr. Diamond first practiced IP law at global law firm White & Case LLP before opening his own practice, Diamond Law Office, LLC, where he was of counsel to the firms Lucas & Mercanti, LLP and Zuber, Lawler & Del Duca, LLP. Paul received his law degree from Fordham University School of Law. He also has a strong scientific background, receiving a B.A. in Biology from The Johns Hopkins University and a Ph.D. in Molecular and Cellular Biology from Harvard University.
News
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ: AVEO) (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company, today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3. Actinium will utilize its AWE technology platform and extensive radiotherapy.
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs and EpicentRx, Inc. (“EpicentRx”), a San Diego-based clinical cancer immunotherapy company today announced that they have entered into a research collaboration to study Actinium’s Actimab-A targeted radiotherapy in combination with RRx-001, EpicentRx’s novel small molecule immunotherapy targeting the CD47-SIRPα axis. Under this s
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that updated data from the recently complete Actimab-A and CLAG-M Phase 1 combination trial being conducted at the Medical College of Wisconsin (MCW) was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and virtua
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that data from the Phase 1 portion of its Actimab-A and venetoclax combination trial in patients with relapsed or refractory acute myeloid leukemia (AML) was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and vi
Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs today announced that positive data from the fully enrolled pivotal Phase 3 SIERRA trial of Iomab-B was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and virtually. Iomab-B is an antibody radiation conjugate (ARC) targeting CD4
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs announced today its participation in the Targeted Radiopharmaceuticals Summit being held virtually December 7 – 9, 2021. The Targeted Radiopharmaceuticals Summit brings together experts and thought leaders in the field with the goal to achieve meaningful clinical efficacy with theragnostic radionuclide therapies in a mono and com
Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that data highlighting an anti-HER2 antibody radiation conjugate (ARC) in combination with a CD47 blocking antibody immunotherapy in solid tumor models are being presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) November 12th – 14th. Actinium evaluated the anti-HER2 anti
Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that data highlighting Actimab-A in combination with a CD47 blocking antibody immunotherapy are being presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) November 12th – 14th. The poster presentation highlights that in multiple AML cell lines, Actimab-A induced an increase
Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) who are fit for intensive therapy has completed the planned dose escalation and patient enrollment. Patients in the fourth and final dose escalation cohort receivt.
Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple abstracts highlighting its Iomab-B and Actimab-A clinical programs have been accepted for presentation at the 63 American Society of Hematology (ASH) Annual Meeting being held in person and virtually in Atlanta, Georgia, December 11 – 14, 2021.
Source 1: https://ir.actiniumpharma.com/press-releases/detail/401
Source 2: https://finance.yahoo.com/quote/MRNA/history?p=MRNA
Source 3: https://fknol.com/list/best-performing/biotech-stocks.php
Source 4: Client Provided Analyst Material HC Wainwright
Source 5: https://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-223.html
Source 6: https://checkrare.com/targeted-therapy-for-acute-myeloid-leukemia/
Source 7: https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics
Source 8: https://cancer.ca/en/cancer-information/cancer-types/acute-myelogenous-leukemia-aml/treatment/relapsed-or-refractory
Source 9: https://www.prnewswire.com/news-releases/actinium-completes-enrollment-in-the-pivotal-phase-3-sierra-trial-of-iomab-b-301377219.html
Source 10: Client Provided Analyst Material William Blair
Source 11: https://d1io3yog0oux5.cloudfront.net/_7a9aad056eac4863c502660ef790af6d/actiniumpharma/db/206/944/pdf/Actinium_InvestorPresentation_September+2021.pdf
Source 12: https://ir.actiniumpharma.com/press-releases/detail/398/pivotal-phase-3-sierra-trial-data-showing-100-bone-marrow
Source 13: https://www.prnewswire.com/news-releases/actinium-further-strengthens-patent-portfolio-with-international-ip-covering-the-composition-and-methods-of-administration-of-iomab-b-antibody-radiation-conjugate-in-the-eu-and-japan-301314557.html
Source 14: https://stockcharts.com/h-sc/ui?s=atnm
Source 15: https://stockcharts.com/h-sc/ui
Source 16: Client Provided Analyst Material Jones Trading
Source 17: https://ir.actiniumpharma.com/press-releases/detail/412/actinium-pharmaceuticals-inc-announces-greater-difference
Source 18: https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-actinium-pharmaceuticals-atnm/
Source 19: https://www.prnewswire.com/news-releases/actinium-announces-multiple-abstracts-highlighting-iomab-b-and-actimab-a-accepted-for-presentation-at-the-63rd-annual-american-society-of-hematology-annual-meeting-301416516.html
Source 20: https://www.actiniumpharma.com/product-pipeline/iomab-b
Source 21: https://www.barchart.com/stocks/quotes/ATNM/opinion
Source 22: https://invezz.com/news/2021/11/09/market-highlights-stocks-react-to-earnings-rele[…]nvests-250-billion-in-autolus-elon-musk-to-sell-10-tesla-stake/
Source 23: https://finance.yahoo.com/news/actinium-pharmaceuticals-inc-announces-greater-123000631.html
Source 24: https://d1io3yog0oux5.cloudfront.net/_6ce8013bee626e168ac4cd2f3de00f02/actiniumpharma/db/206/944/pdf/Actinium_Investor+Presentation_April+2022+%281%29.pdf
Source 25: https://investor.aveooncology.com/news-releases/news-release-details/actinium-pharmaceuticals-inc-and-aveo-oncology-enter-research
Source 26: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-and-epicentrx-announce-strategic-research-collaboration-to-combine-targeted-radiotherapies-with-next-generation-cd47sirp-immunotherapy-301454275.html
